Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03688802 · ClinicalTrials.gov registry record · Phase 2
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
A Phase 2 study, sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03688802 is a Phase 2 study that has completed, run by Oyster Point Pharma. The registered enrollment target is 18 participants.
The verdict
NCT03688802, a Phase 2 study, has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
Interventions
- DRUG OC-01 (varenicline) nasal spray
- DRUG Placebo (vehicle control) nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03688802
The ClinicalTrials.gov registry entry for NCT03688802 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OC-01 (varenicline) nasal spray is the first listed.
NCT03688802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03688802 about?
NCT03688802 is a clinical study titled "Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation". The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo in simulating Goblet Cell and Meibomian Gland function in adult subjects with DED.
What is the current status of trial NCT03688802?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-09-25. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03688802?
The interventions under investigation include: OC-01 (varenicline) nasal spray (DRUG), Placebo (vehicle control) nasal spray (DRUG).
Who is sponsoring clinical trial NCT03688802?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.